Nov 6, 2025 07:14AM Achieve Life Sciences (ACHV) Misses Q3 EPS by 4c

Nov 3, 2025 08:33AM Achieve Life Sciences submits 120-day safety update to FDA for smoking drug

Oct 20, 2025 10:01AM Increasing unusual call option volume: BYND CAN TMQ LBRT EXEL CELC ACHV

Oct 20, 2025 08:31AM Achieve Life Sciences names Erik Atkisson as chief legal officer

Oct 17, 2025 07:30AM Achieve Life Sciences gets FDA national priority voucher for vaping cessation drug

Oct 17, 2025 06:47AM H.C. Wainwright Reiterates Buy Rating on Achieve Life Sciences (ACHV)

Sep 23, 2025 06:38AM H.C. Wainwright Reiterates Buy Rating on Achieve Life Sciences (ACHV)

Sep 22, 2025 08:31AM Achieve Life Sciences publishes COPD smoking cessation data in Thorax

Sep 18, 2025 08:30AM Achieve Life Sciences promotes Craig Donnelly to chief operations officer

Sep 3, 2025 08:31AM Achieve Life Sciences receives FDA acceptance of cytisinicline drug application

Aug 21, 2025 06:35AM H.C. Wainwright Starts Achieve Life Sciences (ACHV) at Buy

Aug 7, 2025 07:36AM Achieve Life Sciences (ACHV) Reports In-Line Q2 EPS

Jun 26, 2025 04:03PM Achieve Life Sciences (ACHV) Announces Proposed Underwritten Public Offering

Jun 26, 2025 04:02PM Achieve Life Sciences (ACHV) Announces Submission of NDA to FDA for Cytisinicline as a Treatment of Nicotine Dependence for Smoking Cessation

Jun 26, 2025 04:02PM Achieve Life Sciences (ACHV) Announces Partnership with Omnicom (OMC) to Execute Integrated, Data-Driven Launch of the First Potential New Treatment for Nicotine Dependence in Nearly Two Decades

May 13, 2025 07:35AM Achieve Life Sciences (ACHV) Tops Q1 EPS by 1c

Apr 21, 2025 11:20AM Achieve Life Sciences (ACHV) Announces Cytisinicline Phase 3 ORCA-3 Trial Publication on Smoking Cessation in JAMA Internal Medicine

Mar 11, 2025 07:31AM Achieve Life Sciences (ACHV) Misses Q4 EPS by 2c

Feb 10, 2025 08:32AM Achieve Life Sciences (ACHV) Announces Positive Outcome of Second Data Safety Monitoring Committee Review for the ORCA-OL Clinical Trial

Jan 7, 2025 08:33AM Achieve Life Sciences (ACHV) Announces Critical Milestone Successfully Reached in ORCA-OL Cytisinicline Clinical Trial Required for NDA Submission

Dec 9, 2024 08:32AM Achieve Life Sciences (ACHV) Appoints Mark Oki as Chief Financial Officer

Dec 4, 2024 12:55AM Oppenheimer Reiterates Outperform Rating on Achieve Life Sciences (ACHV)

Dec 3, 2024 08:42AM Achieve Life Sciences (ACHV) to Advance First Vaping Cessation Therapy After Successful End-of-Phase 2 Meeting with FDA

Nov 14, 2024 06:42AM Rodman & Renshaw Starts Achieve Life Sciences (ACHV) at Buy

Nov 7, 2024 04:09PM Achieve Life Sciences (ACHV) Misses Q3 EPS by 9c

Oct 16, 2024 08:01AM Achieve Life Sciences (ACHV) Appoints Jaime Xinos as Chief Commercial Officer

Oct 10, 2024 02:23PM Jones Trading Reiterates Buy Rating on Achieve Life Sciences (ACHV)

Oct 3, 2024 02:12PM CG Capital Reiterates Outperform Rating on Achieve Life Sciences (ACHV)

Aug 27, 2024 11:12AM Jones Trading Reiterates Buy Rating on Achieve Life Sciences (ACHV)

Aug 26, 2024 04:33PM Achieve Life Sciences (ACHV) Announces Changes in Executive Leadership and Board of Directors

Aug 13, 2024 04:01PM Achieve Life Sciences (ACHV) Misses Q2 EPS by 1c

Jul 31, 2024 08:01AM Achieve Life Sciences (ACHV) Announces FDA Grants Breakthrough Therapy Designation to Cytisinicline for the Treatment of E-Cigarette or Vaping Nicotine Dependence

Jul 29, 2024 08:05AM Achieve Life Sciences (ACHV) Announces $20M Loan Refinancing with Silicon Valley Bank

Jun 28, 2024 04:35PM Achieve Life Sciences (ACHV) Files $200M Mixed Shelf